StockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)

Analysts at StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL) in a note issued to investors on Tuesday. The firm set a “sell” rating on the medical technology company’s stock.

A number of other research analysts have also recently issued reports on BIOL. Benchmark reaffirmed a “speculative buy” rating and issued a $0.40 target price on shares of BIOLASE in a report on Wednesday, October 2nd. Ascendiant Capital Markets dropped their target price on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd.

BIOLASE Price Performance

NASDAQ BIOL opened at $0.00 on Tuesday. BIOLASE has a 52-week low of $0.02 and a 52-week high of $1.94. The stock has a market capitalization of $133,628.00, a P/E ratio of 0.00 and a beta of 0.67. The firm has a 50-day moving average price of $0.03 and a 200 day moving average price of $0.08.

Institutional Inflows and Outflows

An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC lifted its holdings in shares of BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 143,537 shares of the medical technology company’s stock after purchasing an additional 131,248 shares during the period. Virtu Financial LLC owned about 0.43% of BIOLASE worth $27,000 as of its most recent SEC filing. 8.79% of the stock is currently owned by institutional investors.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.